Visual acuity and magnification requirement after ranibizumab in patients with wet age-related macular degeneration;Fernvisus und vergrößerungsbedarf nach ranibizumab bei patienten mit feuchter altersbedingter makuladegeneration

Klinische Monatsblatter fur Augenheilkunde

Volumn 225, Issue 5, 2008, Pages 385-391

  Kloos, Patrik ^a,b   Bernasconi, P ^c   Estermann, S ^a   Bachmann, B ^a   Rutishauser, Y ^a,d   Tholen A ^a  

^a UNIVERSITÄTSSPITAL ZÜRICH   (Switzerland)

^b Kantonsspital ^*  (Switzerland)

^c Clinic Aivla   (Switzerland)

^d Kantonsspital Luzern Augenklinik   (Switzerland)

Author keywords

Age related macular degeneration; AMD; Intravitreal injection; Magnification requirement; Near vision; Ranibizumab

Indexed keywords

RANIBIZUMAB; VERTEPORFIN; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; DRUG EFFECT; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PHOTODYNAMIC THERAPY; RETINA MACULA AGE RELATED DEGENERATION; TREATMENT OUTCOME; VISION; VISUAL ACUITY; CLINICAL TRIAL; MIDDLE AGED; RETINA MACULA DEGENERATION; SPECTACLES; VISUAL DISORDER;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; EYEGLASSES; FEMALE; HUMANS; MACULAR DEGENERATION; MALE; MIDDLE AGED; TREATMENT OUTCOME; VISION, LOW; VISUAL ACUITY;

EID: 47649086335     PISSN: 00232165     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2008-1027252     Document Type: Article

References (15)

1. Bottoni F, Massacesi A, Cigada M et al. Treatment of retinal angiomatous proliferation in age-related macular degeneration: a series of 104 cases of retinal angiomatous proliferation. Arch Ophthalmol 2005; 123: 1644-1650
2. Bressler NM. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization-verteporfin in photodynamic therapy report 2. Am J Ophthalmol 2002; 133: 168-169
3. Brown DM, Kaiser PK, Michels M et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1432-1444
4. Buser F. Der SZB-Test zum Messen des Vergrösserungsbedarfes. Schweizer Optiker 1992; 3: 4-6
5. Ciulla TA, Danis RP, Harris A. Age-related macular degeneration: a review of experimental treatments. Surv Ophthalmol 1998; 43: 134-146
6. Falkenstein IA, Cochran DE, Azen SP et al. Comparison of visual acuity in macular degeneration patients measured with Snellen and early treatment diabetic retinopathy study charts. Ophthalmology 2008; 115 (2): 319-323
7. Faye EE. Low vision. In: Tasman W, Jaeger EA (Hrsg). Duane's clinical ophthalmology, Vol 1. Philadelphia: J. B. Lippincott, 1993: 1-14
8. Fung AE, Lalwani GA, Rosenfeld PJ et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 2007; 143: 566-583
9. Radner W, Willinger U, Obermayer W et al. Eine neue Lesetafel zur Bestimmung von Lesevisus und Lesegeschwindigkeit. Klin Monatsbl Augendeilkd 1998; 213: 174-181
10. Rosenfeld PJ, Brown DM, Heier JS et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1419-1431
11. Sloan L, Brown DJ. Reading carts for selection of optical aids for the partially sighted. Am J Ophthalmol 1963; 55: 1187
12. Thölen AM, Bernasconi PP, Fierz A et al. Lesefähigkeit nach photodynamischer Therapie für altersabhängige Makuladegeneration (AMD) und für hohe Myopie. Ophthalmologe 2003; 100: 28-32
13. Thölen AM, Bernasconi PP, Buser F et al. Magnification requirement after photodynamic therapy with verteporfin for subfoveal predominantly classic choroidal neovascularization due to age-related macular degeneration. Eur J of Ophthalmol 2005; 15: 768-773
14. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials - TAP report no 2. Arch Ophthalmol 2001; 119: 198-207
15. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Verteporfin therapy for subfoveal choroidal neovascularization in age-realted macular degeneration: three-year results of an open-label extension of 2 randomized clinical trials - TAP report no. 5. Arch Ophthalmol 2002; 120: 1307-1314